DrugPatentWatch Database Preview
RITALIN LA Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Ritalin La, and what generic alternatives are available?
This drug has one hundred and forty-two patent family members in thirty-three countries.
The generic ingredient in RITALIN LA is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
Summary for RITALIN LA
| International Patents: | 142 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 62 |
| Clinical Trials: | 99 |
| Patent Applications: | 4,070 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITALIN LA |
| DailyMed Link: | RITALIN LA at DailyMed |
Pharmacology for RITALIN LA
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
Synonyms for RITALIN LA
| 113-45-1 (Parent) |
| 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester, hydrochloride |
| 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride |
| 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R*,R*)-(+-)- |
| 298-59-9 |
| 298M599 |
| AC1L1SQ4 |
| AC1Q5YRN |
| AK116471 |
| AKOS016010356 |
| alpha-phenyl-2-piperidineacetic acid methyl ester hydrochloride |
| AN-23356 |
| API0003340 |
| CAS-298-59-9 |
| CC-30903 |
| CCG-213572 |
| CCRIS 6258 |
| Centedrin |
| Centedrine |
| CHEBI:31836 |
| CHEMBL1722 |
| ciba 4311b |
| Concerta (TN) |
| CS-4658 |
| D-erythro-Methylphenidate Hydrochloride |
| D01296 |
| DSSTox_CID_886 |
| DSSTox_GSID_20886 |
| DSSTox_RID_75843 |
| DTXSID8020886 |
| EINECS 206-065-3 |
| FT-0603372 |
| FT-0672046 |
| FT-0672047 |
| H-Tic-OtBu.HCl |
| HE332528 |
| HY-B1091A |
| JUMYIBMBTDDLNG-UHFFFAOYSA-N |
| LS-42 |
| Medikinet |
| Meridil hydrochloride |
| Metadate |
| Metadate (TN) |
| Metadate CD |
| Metadate ER |
| Methyl .alpha.-phenyl-2-piperidineacetate hydrochloride |
| methyl 2-phenyl-2-(2-piperidyl)acetate hydrochloride |
| METHYL 2-PHENYL-2-(PIPERIDIN-2-YL)ACETATE HCL |
| Methyl 2-phenyl-2-(piperidin-2-yl)acetate hydrochloride |
| methyl 2-phenyl-2-piperidin-2-ylacetate hydrochloride |
| methyl alpha-phenyl-2-piperidine-acetate hydrochloride |
| Methyl alpha-phenyl-2-piperidineacetate hydrochloride |
| Methyl Phenidylacetate Hydrochloride |
| methyl phenyl(piperidin-2-yl)acetate hydrochloride |
| Methylin ER |
| Methylphenidan Hydrochloride |
| Methylphenidate (hydrochloride) |
| Methylphenidate HCl |
| METHYLPHENIDATE HYDROCHLORIDE |
| Methylphenidate hydrochloride (JAN/USP) |
| Methylphenidate hydrochloride [USAN:JAN] |
| Methylphenidate hydrochloride [USP:JAN] |
| Methylphenidate Hydrochloride ER |
| Methylphenidate hydrochloride solution, (Racemic mixture), ampule of 1 mL, 1.0 mg/mL in methanol (as free base), certified reference material |
| Methylphenidate hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| METHYLPHENIDATE HYDROCHLORIDE(SEE ALSO: METHYLPHENIDATE, CAS 113-45-1, NTPNO M20344) |
| Methylphenidate.HCl |
| Methylphenidate(Ritalin) |
| Methylphenidylacetate hydrochloride |
| Metilfenidat hydrochloride |
| MFCD00058191 |
| MLS003922100 |
| NCGC00091942-01 |
| NCGC00257863-01 |
| NSC 169868 |
| NSC-169868 |
| NSC-759278 |
| NSC169868 |
| NSC759278 |
| Pharmakon1600-01505907 |
| QuilliChew ER |
| Quillivant XR |
| Quillivant xr (TN) |
| Rilaline |
| Rilatine |
| Ritalin |
| Ritalin (TN) |
| Ritalin hy drochloride |
| Ritalin hydrochloride |
| Ritalin SR |
| Ritalin-SR |
| SC-83308 |
| SCHEMBL41067 |
| SMR000058998 |
| threo-Methyl |A-phenyl-|A-(2-piperidyl)acetate hydrochloride |
| Tox21_111186 |
| Tox21_200309 |
| TRANSGENIC MODEL EVALUATION (METHYLPHENIDATE HYDROCHLORIDE) (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE) |
| WLN: T6MTJ BYR & VO1 & GH |
US Patents and Regulatory Information for RITALIN LA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | AB1 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-003 | Jun 5, 2002 | AB1 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | AB1 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-002 | Jun 5, 2002 | AB1 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for RITALIN LA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-003 | Jun 5, 2002 | ➤ Sign Up | ➤ Sign Up |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | ➤ Sign Up | ➤ Sign Up |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-001 | Jun 5, 2002 | ➤ Sign Up | ➤ Sign Up |
| Novartis | RITALIN LA | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021284-004 | Apr 10, 2004 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for RITALIN LA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 10 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Extended-release Capsules | 20 mg, 30 mg and 40 mg | ➤ Subscribe | ➤ Sign Up |
Non-Orange Book US Patents for RITALIN LA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,119,163 | Nanoparticulate and controlled release compositions comprising cefditoren | ➤ Sign Up |
| 6,730,325 | Multiparticulate modified release composition | ➤ Sign Up |
| 6,902,742 | Multiparticulate modified release composition | ➤ Sign Up |
| 7,580,712 | Wireless high-speed data network planning tool | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for RITALIN LA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2611506 | ➤ Sign Up |
| Russian Federation | 2236847 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2007011473 | ➤ Sign Up |
| Austria | 411011 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
